Kathleen D. Scott
Kathleen D. Scott's purchase track record
Kathleen D. Scott has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/29/2022 | SPRY | $52K | +47.7% | +14.6% | +6.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Aquestive news highlights biotech valuation dynamics. Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.
Transaction History
| DRMA | ▼ Sell | Open Market | 11 | $13 | 6/16/2026 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 12,500 | $19K | 8/21/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 12,500 | $188K | 8/21/2025 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 50,000 | $75K | 5/20/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 50,000 | $705K | 5/20/2025 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 12,500 | $19K | 10/16/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 12,500 | $200K | 10/16/2024 | View on chart |
| SPRY | ▲ Buy | Option Exercise | 12,500 | $19K | 8/20/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 12,500 | $200K | 8/20/2024 | View on chart |
| SPRY | ▲ Buy | Open Market | 8,250 | $52K | 11/29/2022 | View on chart |
| DRMA | ▲ Buy | Grant | 11,359 | $0 | 10/6/2022 | View on chart |
| DRMA | ▲ Buy | Grant | 9,960 | $0 | 7/7/2022 | View on chart |
| DRMA | ▲ Buy | Grant | 5,826 | $0 | 4/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Dermata Reports Positive Results from Tome Cosmetic Study
Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.
Dermata Reports Positive Results from Tome Cosmetic Study. Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.